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Summary
Dependence on opioid drugs is associated with a range of health and social problems that 
affect individual drug users, their family and friends, and the wider public. This bulletin 
presents information on the clients receiving opioid pharmacotherapy treatment, the 
doctors prescribing opioid pharmacotherapy drugs, and the dosing points that clients 
attend to receive their medication.
Over 48,000 Australians received pharmacotherapy treatment for their opioid 
dependence on a snapshot day in June 2014.
The number of people receiving opioid pharmacotherapy treatment almost doubled 
between 1998 (from around 25,000) and 2014, but growth in client numbers slowed in 
recent years (growing by 0.5–2% a year between 2011 and 2014).
Heroin is the most common opioid drug leading people to pharmacotherapy 
treatment.
Clients were nearly twice as likely to report heroin as an opioid drug of dependence as they 
were for all opioid pharmaceuticals combined, however this varied by jurisdiction.
Methadone continued to be the drug most commonly prescribed; the form in which 
buprenorphine is prescribed is changing.
Around two-thirds (67%) of clients received methadone in 2014, and this has been  
relatively stable since 2006. The remaining third (33%) received 1 of 2 forms of 
buprenorphine. Of these, the proportion receiving buprenorphine only has fallen (from  
24% to 13%) while the proportion receiving buprenorphine combined with naloxone has 
risen (from 5% to 20%) over the same period. Naloxone is added to buprenorphine to  
deter its injection.
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Opioid pharmacotherapy clients are getting older on average.
In 2014, around two-thirds (69%) of clients were aged 30–49, and this has been fairly 
consistent since 2006. However, from 2006 to 2014 the proportion of clients aged less 
than 30 more than halved (from 28% to 10%), and the proportion of clients aged 50 and 
over more than doubled (from 8% to 21%). These trends indicate an ageing population  
of clients in pharmacotherapy treatment.
Males and Indigenous Australians are over-represented in pharmacotherapy 
treatment. 
Around two-thirds (65%) of clients receiving pharmacotherapy in June 2014 were 
male. Where reported, 1 in 10 (10%) clients identified as Indigenous and Indigenous 
Australians were around 3 times as likely to have received pharmacotherapy treatment as 
non-Indigenous Australians.
Prescriber numbers have increased, and most work in the private sector. 
The number of prescribers of opioid pharmacotherapy rose by 31% since 2012 (from 1,768 
to 2,319). In 2014, most prescribers treated 1–5 clients (39%), worked in the private sector 
(82%) and were authorised to prescribe more than 1 type of pharmacotherapy drug (74%).
Most dosing points were located in pharmacies. 
Most clients need to attend a dosing point regularly to take their opioid pharmacotherapy 
drug under supervision. In 2013–14 there were 2,432 dosing point sites in Australia, and 
9 in 10 (89%) were located in pharmacies.
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Introduction
Opioid drug dependence 
Dependence on opioid drugs is associated with a range of health and social problems 
that affect individual drug users, their family and friends, and the wider public. Opioid 
dependence can lead to many problems such as overdose, medical and psychological 
complications, social and family disruption, harms to child welfare, violence and  
drug-related crime, and the spread of bloodborne diseases. It is considered a serious  
public health issue (WHO 2013). 
In 2013, about 3% of Australians had used opioids for non-medical reasons over their 
lifetime, while 1.2% had used heroin (AIHW 2014b). Among those Australians seeking 
treatment for drug and alcohol problems in 2012–13, opioids were a drug of concern in 
about 1 in 8 (13%) treatment episodes (AIHW 2014a). 
What are opioid drugs?
Opioids are chemical substances that have a morphine-type action in the body. Opioid 
drugs depress the central nervous system and are widely used to treat pain due to their 
analgesic effect. Other effects include sedation and euphoria, however repeated use of 
opioids can lead to drug dependence—a chronic, relapsing condition (NSW Health 2006).
Opioid drugs include:
•  illicit opioids, predominantly heroin (WHO 2013)
•   prescription opioids (whether prescribed for the person or obtained illicitly) such as 
morphine and oxycodone (Roxburgh et al. 2011)
•   over-the-counter opioids in which the opioid drug codeine is combined with a  
non-opioid analgesic such as paracetamol or ibuprofen (Nielsen et al. 2010).
Opioid pharmacotherapy treatment
Opioid dependence is a condition requiring long-term treatment. Opioid pharmacotherapy 
treatment is one of the main treatment types used for opioid drug dependence and 
involves replacing the opioid drug of dependence with a legally obtained, longer-lasting 
opioid that is taken orally. It reduces or eliminates withdrawal symptoms and drug 
cravings (NDARC 2004). Research suggests that pharmacotherapy treatment reduces 
heroin use, other opioid substance misuse and associated criminal behaviour. It also 
improves physical and mental health and social functioning (Ritter & Chalmers 2009).
In Australia, 3 medications are registered for long-term maintenance treatment for  
opioid-dependent people:
•  methadone oral liquid (available since 1969)
•  buprenorphine tablet (available since 2000)
•   buprenorphine-naloxone tablet (available since 2005) or film (available since 2011) 
(DoHA 2007; DoHA 2012) (see Glossary for further details).
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How is opioid pharmacotherapy provided in Australia?
The current Australian opioid pharmacotherapy system seeks to strike a balance between 
maximising accessibility of treatment and minimising the risks associated with  
non-compliance (injecting medication) and diversion (selling or swapping medication) 
(Ritter & Chalmers 2009). Methadone and buprenorphine are Schedule 8 (controlled) 
drugs, which means there are strict regulations associated with their use (Ritter & 
Chalmers 2009).
Clients seek or are referred to treatment for their opioid dependence. A health professional 
who is authorised to provide opioid pharmacotherapy (a prescriber) prescribes methadone, 
buprenorphine or buprenorphine-naloxone as part of the client’s treatment plan. Clients 
are not usually given a whole course of their medication for use at home. Rather, the client 
attends a dosing point regularly and takes 1 dose of their prescribed medication under the 
supervision of a pharmacist or other health professional. Some takeaway doses may be 
given to eligible clients. Where takeaway dosing is permitted, it is recommended (for clients 
on buprenorphine) that buprenorphine-naloxone is prescribed (DoHA 2007). For more 
information on dosing, see the ‘Dosing points’ section of this bulletin. 
Each state and territory has rules about how prescribers are authorised to prescribe 
methadone, buprenorphine and buprenorphine-naloxone. For more information, see the 
‘Prescribers’ section of this bulletin and Appendix A (online).
About the NOPSAD collection
The National Opioid Pharmacotherapy Statistics Annual Data (NOPSAD) collection 
is a set of jurisdictional data that includes information about clients accessing 
pharmacotherapy for the treatment of opioid dependence; prescribers participating in the 
delivery of pharmacotherapy treatment; and dosing sites that clients attend to receive their 
medication. Data are reported on a snapshot day in June each year.
The information about the provision of opioid pharmacotherapy treatment in this bulletin 
is based on the data from the NOPSAD collection. The bulletin is part of the National 
opioid pharmacotherapy statistics 2014 release which includes supplementary tables  
(those with a prefix of S) and web pages which are available from the Australian Institute 
of Health and Welfare (AIHW) website at:  
<http://www.aihw.gov.au/national-opioid-pharmacotherapy-statistics-annual-data-collection/>.
Clients
On a snapshot day in June 2014, 48,393 clients were receiving pharmacotherapy treatment 
in Australia, a rise of 951 (or 2%) between 2013 and 2014 (Figure 1). In contrast, between 
1998 and 2004, and again between 2007 and 2010, client numbers grew by 5–13% a year. 
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Source: Table S1.
Figure 1: Clients receiving pharmacotherapy treatment on a snapshot day, 1998 to 2014
Nationally, the number of clients per 10,000 people in the population increased from 15 
in 1998 to 24 in 2010, but has since remained stable at 24 (Table S1). In 2014, New South 
Wales had the highest rate of clients (26 per 10,000 population), followed by Victoria 
(24 per 10,000) and the Australian Capital Territory (24 per 10,000). The Northern 
Territory had the lowest rate of clients (6 per 10,000 population). The low rate of clients in 
the Northern Territory may be partially attributable to the limited availability of heroin 
(Moon 2014), the impact of remote locations on treatment delivery, and a highly mobile 
population. Rates for all states and territories have remained relatively stable over the last 
4 collection years (Table S2).
On a snapshot day in June 2014, 67% of clients received methadone, 13% received 
buprenorphine, and 20% received buprenorphine-naloxone (Table S4). However, it should 
be noted that New South Wales does not report clients receiving buprenorphine-naloxone 
separately—these clients are included in the number of clients receiving buprenorphine. 
When New South Wales data are excluded, in the rest of Australia 61% of clients received 
methadone, 5% received buprenorphine, and 34% received buprenorphine-naloxone.
Nationally, from 2008 to 2014, the proportion of clients receiving methadone fell slightly 
from 70% to 67% (Figure 2). Over the same period, the proportion of clients receiving 
buprenorphine fell from 15% to 13%, while the proportion receiving buprenorphine-naloxone 
rose from 16% to 20%. These data indicate that buprenorphine-naloxone prescription is 
replacing buprenorphine prescription to some extent. This is in keeping with national 
guidelines (DoHA 2007), which recommend that buprenorphine-naloxone should be 
preferred over buprenorphine for most clients receiving takeaway doses. 
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Notes
1.   Data prior to 2008 should be interpreted with caution, as separate data collection of buprenorphine-naloxone started at different times: 2006 
for Vic, WA, SA, NT; 2007 for Tas and the ACT; and 2008 for Qld.
2.   NSW counts ‘buprenorphine-naloxone’ as ‘buprenorphine’. See Appendix A (online).
Source: Table S4. 
Figure 2: Clients receiving pharmacotherapy treatment on a snapshot day, by pharmacotherapy 
type, 2006 to 2014
The proportion of clients receiving each of the 3 pharmacotherapies varies across states 
and territories (Figure 3). In 2014, methadone was the most common pharmacotherapy 
in all jurisdictions except for the Northern Territory. The Australian Capital Territory 
and New South Wales had the highest proportion of clients receiving methadone (79% 
and 75% respectively). In contrast, only 28% of clients in the Northern Territory were 
prescribed methadone. The Northern Territory had the highest proportion of clients 
receiving buprenorphine-naloxone (62%). Buprenorphine-naloxone is the default treatment 
drug for the main pharmacotherapy program in the Northern Territory.
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Age and sex
In 2014, around two-thirds (69%) of clients were aged 30–49, and this proportion has 
been fairly consistent since 2006 (Figure 4). However, from 2006 to 2013 the proportion 
of clients aged less than 30 more than halved (from 28% to 10%), and the proportion of 
clients aged 50 and over more than doubled (from 8% to 21%). This trend indicates an 
ageing cohort of people receiving opioid pharmacotherapy treatment. This trend towards 
pharmacotherapy clients being older has also been observed overseas (see, for example, 
Doukas 2011 and Dürsteler-MacFarland et al. 2011) and may be due to:
•  methadone treatment having been available for more than 40 years
•   pharmacotherapy treatment reducing the risk of premature death, resulting in some 
clients remaining in treatment for decades
•  clients seeking treatment for the first time at an older age.
Note: NSW counts ‘buprenorphine-naloxone’ as ‘buprenorphine’. See Appendix A (online) for further details.
Source: Table S4.
Figure 3: Clients receiving pharmacotherapy treatment on a snapshot day, by pharmacotherapy 
type, states and territories, 2014
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 In 2014, clients ranged in age from their late-teens to 90. The median age of clients across 
all pharmacotherapy types was 40 years in 2013 and 2014, compared with 39 in 2012 
and 38 in 2011 (the first year single-year age data were collected). At a state and territory 
level, clients in Victoria had the youngest median age (38 years) and clients in New South 
Wales had the oldest median age (42 years) (Table S5).
In 2014, methadone was the most commonly dispensed pharmacotherapy across all age 
groups (Figure 5). For older clients, the proportion receiving methadone was higher than 
for younger clients. Conversely, younger clients were more likely to receive buprenorphine 
or buprenorphine-naloxone than older clients. As buprenorphine was registered in 
Australia for opioid pharmacotherapy in 2000, and buprenorphine-naloxone was only 
registered in 2005 (DoHA 2007), one explanation for the observed trend might be 
that some older, long-term clients first entered treatment when methadone was the only 
available pharmacotherapy for opioid dependence and they have remained on this regime.
Note: Collection of age began in 2006.
Source: Table S6.
Figure 4: Clients receiving pharmacotherapy treatment on a snapshot day, by age group, 2006 to 2014
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On a snapshot day in June 2014, around two-thirds (65%) of clients receiving 
pharmacotherapy were male. This proportion was consistent across states and 
territories (ranging from 60% in Tasmania to 67% in the Northern Territory), and by 
pharmacotherapy type—64% of clients receiving methadone, 65% of clients receiving 
buprenorphine and 67% of clients receiving buprenorphine-naloxone (Table S7).
There was little difference in age of male and female pharmacotherapy clients; however, 
females tended to be slightly younger. Clients aged 25‒34 were more likely to be female, 
while those aged 50 and over were more likely to be male (Table S22). 
The rate of people receiving pharmacotherapy was highest between ages spanning early 
30s to mid-50s for both males and females (Figure 6). The rate peaked at the age of 
37 for males and 36 for females (with 81 clients for every 10,000 males aged 37 in the 
population, and 46 clients for every 10,000 females aged 36). Males were generally more 
likely—and in some cases about twice as likely—to be receiving pharmacotherapy when 
compared to females of the same age.
Notes 
1.  Data for Victoria were not available for age by pharmacotherapy type.
2.   New South Wales count ‘buprenorphine-naloxone’ as ‘buprenorphine’. As a result, the proportion of clients receiving buprenorphine-naloxone 
nationally is likely to be higher than reported in this figure. See Appendix A (online) for further details.
Source: Table S6.
Figure 5: Clients receiving pharmacotherapy treatment on a snapshot day, by age group and 
pharmacotherapy type, 2014
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Aboriginal and Torres Strait Islander people
In 2014, 6 states and territories were able to provide information about the Indigenous 
status of clients receiving pharmacotherapy treatment. Victoria and Western Australia 
did not report the Indigenous status of their clients, with the result that Indigenous 
status was only reported for around two-thirds (30,749 or 64%) of clients in the collection. 
The analysis of the 2014 data that follows should be treated with caution due to the high 
proportion of clients (42%) for whom Indigenous status is either not reported or not stated.
In 2014, 2,994 (10%) of clients identified as being of Aboriginal and/or Torres Strait 
Islander origin (hereafter referred to as Indigenous Australians) (Table S9). The 
proportion of clients who were Indigenous Australians ranged from 5% in Queensland to 
12% in the Northern Territory.
Overall, the rate of Indigenous clients receiving pharmacotherapy treatment was  
53 per 10,000 Indigenous Australians. When compared to the rate for non-Indigenous 
clients (17 clients per 10,000 non-Indigenous Australians), Indigenous Australians are 
over-represented in pharmacotherapy treatment for opioid dependence. Among the 
states and territories for which data were available, the Australian Capital Territory and 
New South Wales had the highest rates of Indigenous clients (136 clients per 10,000 
Indigenous Australians, and 100 per 10,000 respectively), and Queensland and the 
Northern Territory the lowest, consistent with their low overall rate of pharmacotherapy 
(17 clients per 10,000 Indigenous Australians and 2 per 10,000 respectively). (Note: The 
high rate in the Australian Capital Territory should be interpreted with caution as it has a 
small Indigenous Australian population.)
Seven in 10 (70%) Indigenous clients received methadone (Table S9). 
Notes
1.   Unit record data were used to produce this figure. Records were available for 58% of total clients receiving pharmacotherapy on a snapshot day 
in 2014. Vic and Qld data were not available.
2.  Australian population estimates for June 2014 were used to produce this figure.
Source: Table S21.
Figure 6: Clients receiving pharmacotherapy treatment on a snapshot day, by age and sex, 2014
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Opioid drug of dependence and client status
In 2013, two new data items were collected and reported—clients’ opioid drugs of 
dependence (the drugs leading people to seek opioid pharmacotherapy treatment), and 
client status (new, ongoing or re-admitting client, and client transferring from another state/
territory jurisdiction). Over the 2 years these data items have been collected, high rates of 
‘not stated’ and ‘not reported’ responses were received (40% and 49% respectively), therefore 
the following information should be interpreted with caution, as there is no information on 
the extent to which those reporting and those not reporting differ on these issues. 
Opioid pharmacotherapy clients receive treatment for a range of drugs of dependence, 
including illicit opioids (such as heroin) and pharmaceutical opioids, which are available 
illicitly, by prescription (such as morphine and oxycodone) or over the counter (such as 
codeine-paracetamol combinations).
At the national level, in 2014, clients were nearly twice as likely to report heroin as an 
opioid drug of dependence (18,806 clients) than they were for opioid pharmaceuticals 
(10,161 clients) (Figure 7). Oxycodone (2,357 clients), methadone (2,314 clients) and 
morphine (2,249) were the next most commonly reported drugs of dependence; however, 
pharmacotherapy drugs may be subject to misreporting if a client’s treatment drug is 
reported in place of the opioid drug of dependence leading a client to seek treatment. In 
addition, differences in reporting for Victoria mean that data on opioid drug of dependence 
should be interpreted with caution (see footnote in Figure 7 for more information).
Heroin was the most common drug of dependence in all states and territories, except 
Tasmania and the Northern Territory, where morphine was the most common. 
Notes
1.   All jurisdictions except Victoria reported 1 opioid drug of dependence per client. Victoria reported multiple opioid drugs of dependence  
(up to 5) for a maximum of 1% of clients—these data have been included without amendment. 
2.  ‘Not stated/not reported’ also includes ‘inadequately described’ responses.
Source: Table S10.
Figure 7: Clients receiving pharmacotherapy treatment on a snapshot day, by opioid drug of 
dependence, states and territories, 2014
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Clients interact with the pharmacotherapy treatment system in a number of ways. A 
client’s status may differ according to whether they are: receiving treatment for the first 
time (new); re-entering treatment after a lapse (re-admission); continuing treatment 
(ongoing); or transferring from another state/territory jurisdiction (interstate transfer). 
On a snapshot day in June 2014, client status data were provided for Victoria, Queensland, 
Western Australia and Tasmania (Table S11). In these 4 jurisdictions, the majority of 
clients were classed as ongoing. This was highest in Tasmania (99%), followed by Western 
Australia (95%), Victoria (78%) and Queensland (70%). The proportion of re-admitting 
clients ranged from 24% in Queensland to less than 1% in Tasmania. New clients 
comprised only a small proportion of clients in all 4 jurisdictions (no greater than 10%).
Prescribers
Medical personnel, such as general practitioners and medical specialists, prescribe opioid 
pharmacotherapies. Each state and territory has a registration process through which 
prescribers can undergo training and become registered or authorised to prescribe opioid 
pharmacotherapies to clients. Data on all registered or authorised prescribers are included 
in this report, except for New South Wales, Western Australia and South Australia, 
where prescribers are included only if they are actively prescribing for at least 1 client on 
the snapshot day (see Table A2 of online Appendix A for further details). New South 
Wales (9), Western Australia (3) and South Australia (3) have prescribers who prescribe 
in more than 1 location, and as such are counted twice. This will lead to slightly deflated 
client to prescriber ratios. 
Being authorised or registered to prescribe pharmacotherapy for opioid dependence 
does not necessarily mean that the prescriber will prescribe this medication during any 
given year. Prescribers who have prescribed pharmacotherapy for a client with opioid 
dependence in a given financial year are referred to as ‘active prescribers’ (see Glossary for 
more information).
Nationally, there were 2,319 prescribers authorised to prescribe 1 or more 
pharmacotherapy drugs in 2014 (Table S15). This was a rise of 294 prescribers (15%) from 
2013 and (31%) since 2012. Of these 2,319 prescribers, 74% (1,726) were authorised to 
prescribe more than one pharmacotherapy type, 11% (262) were authorised to prescribe 
methadone only, and 9% (207) were authorised to prescribe buprenorphine-naloxone 
only. The remaining 5% (124) were located in New South Wales and were authorised to 
prescribe buprenorphine and/or buprenorphine-naloxone, but reported as ‘buprenorphine 
only’ (Table S15).
Over the period 2006 to 2014, the proportion of prescribers authorised to prescribe more 
than 1 pharmacotherapy type rose from 51% to 74% (Figure 8). The rise in the proportion 
of prescribers authorised to prescribe buprenorphine-naloxone only (from 1% in 2011 to 9% 
in 2014) occurred mainly in South Australia, and is due to the introduction of the Suboxone® 
Opioid Substitution Program (see Table A1 of online Appendix A for more information). In 
Victoria, as of 2013, general practitioners could prescribe buprenorphine-naloxone for up to 
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5 patients without the need to attend training (Vic Health 2013). This also had an impact 
on the increased proportion of buprenorphine-naloxone-only prescribers.
All prescribers in Queensland, Western Australia, the Australian Capital Territory and the 
Northern Territory were registered to prescribe more than 1 drug type in 2014  (Table S15).
Where do prescribers work and how many clients do they treat?
Prescribers are classified according to the sector in which they are working when 
prescribing pharmacotherapy drugs to clients, that is, private, public or correctional 
facility. Of the 2,319 prescribers authorised to prescribe pharmacotherapy drugs in 2014, 
82% (1,898) were private prescribers, 13% (296) were public prescribers, and 4% (83) were 
prescribers working in a correctional facility (Table 1).
Table 1: Prescribers, by prescriber type, states and territories, 2014
Prescriber type NSW Vic Qld WA SA Tas ACT NT Aust
Public prescriber 152 — 83 23 16 12 5 5 296
Private prescriber 502 977 126 68 164 19 42 — 1,898
Public/private prescriber(a) 36 — 5 — — — 1 — 42
Correctional facility 26 18 7 23 5 2 1 1 83
Total 716 995 221 114 185 33 49 6 2,319
(a)  In NSW, Qld and the ACT, these numbers relate to prescribing that cannot be separated into a single prescriber type.
Note: The states and territories have different guidelines and policies regarding training and registration to prescribe opioid pharmacotherapy types.  
In South Australia, for example, 109 out of 185 prescribers treat a total of 157 clients (under the SOSP). See Appendix A (online) for more information.
Note: NSW counts ‘buprenorphine-naloxone’ as ‘buprenorphine’. See Appendix A (online) for further details.
Source: Table S15.
Figure 8: Prescribers, by pharmacotherapy type, 2006 to 2014
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In 2014, Victoria had no public prescribers, and so had the highest proportion of private 
prescribers (98%). It was followed by South Australia and the Australian Capital 
Territory (89% and 86% private prescribers respectively). The Northern Territory had 
the highest proportion of public prescribers (83%), followed by Queensland (38%) and 
Tasmania (36%).
Of the 48,393 clients receiving treatment in Australia on the snapshot day in June 2014,  
63% (30,550) received treatment from a private prescriber, 24% (11,479) received 
treatment from a public prescriber, and 7% (3,285) received treatment from a  
correctional facility prescriber (Table S3). These proportions have remained stable  
since 2006 (Table S12).
Private prescribers treated the majority of clients in New South Wales, Victoria, Western 
Australia, South Australia and Tasmania. Public prescribers treated the majority of 
clients in Queensland, the Australian Capital Territory and the Northern Territory 
(Table S3). This pattern is similar to that observed in 2013 for all jurisdictions.
Clients per prescriber
Data on the number of clients receiving pharmacotherapy treatment per prescriber 
were collected for the first time in 2014. Prescribers most commonly treated 1–5 clients. 
Nationally, on a snapshot day in June 2014, 39% of pharmacotherapy prescribers were 
treating 1–5 clients and 25% of prescribers were not treating any clients. Across states and 
territories, the proportion of pharmacotherapy prescribers treating 1–5 clients ranged 
between 16% in Queensland and 68% in South Australia (Table S17).
On a snapshot day in 2014, 2,319 prescribers were treating an average of 21 clients each. 
Over the 5-year period from 2010, there has been a steady decline in ratio of clients to 
prescribers (from 32 clients) (Figure 9). Low growth in client numbers (2% between 2013 
and 2014) coupled with relatively high growth in prescriber numbers (15% between 2013 
and 2014) has meant that the client-per-prescriber ratio fell in 2014. This continues a 
recent trend, with the client-per-prescriber ratio falling over the last 4 collection years.
Between 2013 and 2014, the number of clients per prescriber fell in the larger 
jurisdictions, but rose in Tasmania (from 18 to 21), the Australian Capital Territory (from 
14 to 19), and the Northern Territory (from 12 to 26). In relative terms, Queensland had 
a notable drop (from 33 to 29), as did Western Australia (from 34 to 30).
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In 2014, prescribers working in the public sector had, on average, nearly 2.5 times as many 
clients as prescribers working in the private sector (39 clients per prescriber compared 
with 16) (Table S20). However, both sectors saw decreases in client ratios from 2013, with 
ratios for public prescribers dropping from 49 to 39 and private prescribers from 19 to 16. 
Public prescribers in the Australian Capital Territory (105 clients) and South Australia 
(70 clients) had a relatively high average number of clients. Private prescribers had a 
lower average number of clients than public prescribers in all states and territories except 
Victoria, which had no public prescribers.
Prescribers working in correctional facilities had an average of 40 clients nationally, but at 
a state and territory level this varied widely, from 2 clients per prescriber in Tasmania to 
107 clients per prescriber in the Australian Capital Territory (Table S20).
Does treatment vary between sectors?
In 2014, methadone was the most commonly prescribed drug across all sectors (Table S12). 
However, prescribers in correctional facilities were far more likely to prescribe methadone 
(87% of clients) when compared with private (66%) or public prescribers (61%). Private 
prescribers were the most likely to prescribe buprenorphine-naloxone (23%) compared 
with public (22%) or correctional facility (6%) prescribers. Given that clients prescribed 
buprenorphine-naloxone in New South Wales are reported as receiving buprenorphine, 
the proportion of clients actually receiving buprenorphine-naloxone nationally is likely to 
be an underestimate.
Note: In South Australia, the decline in clients per prescriber is attributed to the introduction of the SOSP. On a snapshot day in 2014, 109 
prescribers registered under the SOSP treated a total of 157 clients, while the remaining 76 prescribers treated a total of 3,016 clients.
Source: Table S19.
Figure 9: Average number of clients per prescriber, states and territories, 2010 to 2014
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The client group that particular prescriber types treat can vary depending on the demographic 
features of the clients. Based on 2014 unit record data from 6 states and territories, correctional 
facility prescribers were more likely to treat younger clients (Table S25)—correctional 
facilities treated clients aged under 30 at over twice the rate seen for all prescribers. Public, 
private and public/private prescribers served similar client groups. 
Public, private and public/private prescriber types were generally similar in terms of the 
proportion of male and female clients treated, each treating about twice as many males as 
females (Table S24). Correctional facilities were different, with about 9 in 10 clients  
being male.
Dosing points
At the start of treatment, clients need to attend the clinic or pharmacy to take their 
dose under supervision. However, the requirement to travel regularly to the dosing point 
can be a barrier to both ongoing participation in treatment and social reintegration. To 
overcome these issues, there is a provision for takeaway doses for stable clients in some 
circumstances (DoHA 2007). Policies on takeaway dosing vary by state or territory.  
For more information, refer to the individual state and territory guidelines for treating 
opioid dependence in Table A3 of Appendix A (online). Where takeaway dosing 
is allowed, it is preferred that clients on buprenorphine are given the combination 
buprenorphine-naloxone product as the ‘properties of the combination product are 
intended to limit the abuse potential of buprenorphine’ (DoHA 2007).
In 2013–14 there were 2,432 dosing points in Australia, a rise of 77 (3%) from 2012–13 
(Table S16). In the same period the number of dosing points rose in all states and 
territories (with the exception of the Australian Capital Territory, which stayed the same). 
Nationally, in 2013–14 the majority of dosing points were pharmacies (89%), which 
were the most common dosing point sites in all states and territories (Table 2). These 
proportions are very similar to those observed in previous years. 
Table 2: Dosing point sites, states and territories, 2013–14
Dosing point sites NSW(a) Vic Qld WA SA Tas ACT NT Aust Aust (%)
Public clinic 36 — 10 1 2 2 1 2 54 2.2
Private clinic 12 — 10 — — — — — 22 0.9
Pharmacy 700 478 436 242 197 60 32 9 2,154 88.6
Correctional facility 2 11 4 2 8 1 1 1 30 1.2
Other(b) 75 15 77 3 1 1 — — 172 7.1
Total (number) 825 504 537 248 208 64 34 12 2,432 100.0
Total (%) 33�9 20�7 22�1 10�2 8�6 2�6 1�4 0�5 100�0 � �
(a)   See Appendix A (online) for more information about NSW. NSW and WA correctional dosing points are reported as 2 sites.
(b)   The category ‘other’ includes hospitals, mobile dosing sites, community health clinics, non-government organisations, doctors’ surgeries and dosing 
points ‘not stated’.
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What is the relationship between clients and dosing points?
Of the 48,393 clients receiving treatment on the snapshot day in June 2014, the majority 
(71%) dosed at a pharmacy. Other common sites for dosing were public clinics (8% of 
clients), private clinics and correctional facilities (7% each) (Table S13). Data on the 
number of clients receiving pharmacotherapy treatment per dosing point were collected 
for the first time in 2014. The most common number of clients per dosing point was 1–5 
clients. Nationally, on a snapshot day in June 2014, 31% of dosing points treated 1–5 
clients, 20% treated 21–50, and 18% 11–20. The pattern of client numbers per dosing 
point varied greatly across states and territories (Table S18).
On average, 20 clients were dosed at each dosing point site (Figure 10). However, this 
varied significantly by the type of dosing point. Private clinics dosed, on average, more 
than 10 times as many clients as each pharmacy (165 clients per dosing point compared to 
16). Correctional facilities dosed an average of 113 clients, but this number is inflated as 
New South Wales and Western Australia report all correctional dosing point sites under 
2 sites. When New South Wales and Western Australian data are excluded, correctional 
facilities dosed an average of 55 clients (tables 2 and S13).
Nationally, the average number of clients per dosing point rose from around 19 in 2006, 
peaking at around 21 between 2010 and 2012 (Figure 11). In 2014, the ratio fell back 
slightly to 20. At a state and territory level, the ratio of clients per dosing point rose or 
remained relatively stable between 2006 and 2012. In 2014, Victoria (28) had the highest 
ratio of clients per dosing point followed by the Australian Capital Territory (27) and 
New South Wales (23) (Figure 11). 
Note: NSW and WA correctional dosing points are reported as 2 sites.
Source: Tables 2 and S13.
Figure 10: Average number of clients per dosing point, 2014
18
National opioid pharmacotherapy statistics 2014
While the majority of clients were dosed at pharmacies, a larger proportion of clients who 
received buprenorphine-naloxone were dosed at a pharmacy (86%) than those receiving 
methadone (71%) or the buprenorphine-only product (57%). A larger proportion of 
clients who received methadone were dosed in a correctional facility (9%) than those who 
received buprenorphine only (4%) or buprenorphine-naloxone (2%). These proportions have 
remained similar for about the last 5 years (Table S14). The proportion of clients dosed with 
buprenorphine-naloxone may be higher than reported, as clients receiving this treatment in 
New South Wales are reported as receiving buprenorphine. (Refer to Table S13 for a further 
breakdown of clients by pharmacotherapy type, dosing points, and state and territory.)
As with prescriber types, the characteristics of the client group treated at particular 
dosing point types are not uniform. For those states and territories for which data were 
available, more pharmacy dosing points treated an older client group (those aged 50 and 
over) in 2014 than other dosing point types (Table S27). Correctional facility dosing 
points, on the other hand, dosed a much younger client group than other dosing point 
types. The client groups dosed at public clinics, private clinics and hospitals were similar.
All dosing point types treated more males than females, reflecting the overall proportion 
of males and females receiving pharmacotherapy treatment. The proportion of male clients 
ranged from 61% for pharmacy dosing points to 88% for correctional facility dosing points 
(Table S26). Correctional facility dosing points dosed 7 male clients for every female client. 
There are a number of different pathways that clients take from where they are prescribed 
pharmacotherapy to where they are given their treatment dose. On a snapshot day in 
June 2014, the large majority of clients dosed at public clinics were prescribed by public 
prescribers (Table 3). Likewise, almost all clients dosed at private clinics were dosed by 
private prescribers. For clients treated at pharmacies, about 3 in 10 were prescribed by 
public prescribers and about 6 in 10 by private prescribers.
Source: Table S19.
Figure 11: Average number of clients per dosing point, states and territories, 2010 to 2014
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Table 3: Clients receiving pharmacotherapy treatment on a snapshot day, by prescriber type and dosing  
point type, 2014 (per cent)
Dosing point type
Prescriber type
Public 
clinic
Private 
clinic Pharmacy
Correctional 
facility Hospital Other Not stated
All dosing
points
Public prescriber 7.7 0.4 15.4 0.3 0.3 — 4.7 28.8
Private prescriber 2.0 9.2 31.1 0.3 0.2 0.1 9.2 52.1
Public/private prescriber 3.0 0.8 5.6 0.5 0.5 — 0.7 11.1
Correctional facility 0.1 — 0.2 6.6 — 0.2 1.0 8.0
Total 12�8 10�4 52�3 7�6 1�0 0�3 15�6 100�0
Note: Unit record data were used to produce this table. Records were available for 57% of total clients receiving pharmacotherapy on a snapshot day in 2014.  
Vic and Qld data were not available.
Glossary
Buprenorphine (Subutex®): Buprenorphine acts in a similar way to methadone, but is 
longer-lasting and may be taken daily or every second or third day. Two buprenorphine 
preparations are registered in Australia for the treatment of opioid dependence: a product 
containing buprenorphine only and a combined product containing buprenorphine and 
naloxone. The buprenorphine-only product is available as a tablet containing buprenorphine 
hydrochloride that is administered sublingually (by dissolving under the tongue)  
(DoHA 2007).
Buprenorphine-naloxone (Suboxone®): The combination buprenorphine-naloxone 
product is a sublingual tablet or film containing buprenorphine hydrochloride and naloxone 
hydrochloride (DoHA 2012). It is recommended that buprenorphine-naloxone should be 
prescribed in preference to buprenorphine for most clients receiving takeaway doses  
(DoHA 2007). This is because, when taken as intended by dissolving the tablet or film under 
the tongue, the combined product acts as if it was buprenorphine alone. However, if the 
combined product is injected, naloxone can block the effects of buprenorphine and increases 
opioid withdrawal symptoms. This reduces the risk that those receiving buprenorphine-naloxone 
as a takeaway dose will inject it or sell it to others to inject (Chapleo & Walter 1997; DoHA 2007; 
Dunlop 2007).
client: a person registered as receiving opioid pharmacotherapy treatment on the  
snapshot day.
correctional facility prescribers: prescribers who work in prisons or other correctional services.
dosing point site: a place at which at least 1 client is provided a pharmacotherapy drug 
on the snapshot day. Sites include public and private clinics (such as methadone clinics), 
pharmacies, correctional facilities, hospitals (admitted patients and outpatients) and other 
locations such as community health centres and doctors’ surgeries.
Methadone (Methadone Syrup®, Biodone Forte®): a synthetic opioid used to treat heroin 
and other opioid dependence. It reduces opioid withdrawal symptoms, the desire to take 
opioids and the euphoric effect when opioids are used. It is taken orally on a daily basis 
(DoHA 2007).
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prescriber: a registered prescriber who is accredited and/or authorised to prescribe 
a pharmacotherapy drug and who has not been recorded as ceasing this registration 
before the snapshot day. More specifically, prescribers are included in the count if they 
are registered or active prescribers, that is, prescribers who are scripting at least 1 client 
during the reporting period (that is, each financial year).
prescriber type: the sector (public or private) in which the prescriber is practising when 
prescribing pharmacotherapy drugs.
private prescribers: prescribers who work in organisations that are not controlled by 
government, such as private general practice clinics.
public prescribers: prescribers who work in organisations that are part of government or 
are government-controlled, such as public drug and alcohol clinics and public hospitals.
specified/snapshot day or snapshot day: a particular day, usually in June each year, on 
which clients are counted for the NOPSAD collection. The snapshot day varies between 
states and territories, but allows the number of clients to be estimated at a single point in 
time. See Appendix A (online) for information about the use of the snapshot day for each 
state and territory.
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Abbreviations
ACT Australian Capital Territory
AIHW Australian Institute of Health and Welfare
AODTS NMDS Alcohol and Other Drug Treatment Services National Minimum   
 Data Set
DoH (Australian Government) Department of Health
NOPSAD National Opioid Pharmacotherapy Statistics Annual Data
NSW New South Wales
NT Northern Territory
Qld Queensland
SA South Australia
Tas Tasmania
Vic Victoria
WA Western Australia
Symbols
— nil or rounded to zero
. . not applicable
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More information and related publications
Supplementary data tables (those with a prefix of S) containing the information referred 
to in this bulletin are part of this release and can be downloaded free of charge from 
<http://www.aihw.gov.au/publication-detail/?id=60129551121>. Additional material, 
including explanatory notes and a data quality statement, are also available in online 
appendixes A and B.
For more information on alcohol and other drug use and treatment services in Australia, 
see the AIHW website <http://www.aihw.gov.au/alcohol-and-other-drugs/>. 
The following AIHW publications also contain information on drug use and treatment:
•   National Drugs Strategy Household Surveys (NDSHS)  
<http://www.aihw.gov.au/alcohol-and-other-drugs/ndshs/>
•   Alcohol and other drug treatment services in Australia  
<http://www.aihw.gov.au/alcohol-and-other-drugs/aodts/>
•   Prisoner health services in Australia 2012 
<http://www.aihw.gov.au/publication-detail/?id=60129548273>.
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